SCHEMBL21361437

SCHEMBL21361437

Cc1cc(F)ccc1N1CCN(C(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
GAA P10253 4/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 5/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ADAMTS5 Q9UNA0 1/20 0.41
MAPT P10636 5/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
MEN1 O00255 1/20 0.40
THRB P10828 1/20 0.40
NR4A1 P22736 1/20 0.40
KMT2A Q03164 1/20 0.40
PTK2B Q14289 1/20 0.40
F12 P00748 1/20 0.40
HTR6 P50406 1/20 0.40
AVPR1A P37288 1/20 0.40
HTT P42858 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8137240 0.85 ALDH1A1 (0.46) DRD2GAALMNAALDH1A1L3MBTL1
SCHEMBL21361622 0.83 ALDH1A1 (0.45) GAALMNASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21447968 0.83 MAPT (0.53) DRD2DRD4GAALMNASMN1; SMN2
SCHEMBL14922277 0.81 ALDH1A1 (0.67) DRD2DRD4GAALMNASMN1; SMN2
SCHEMBL1813298 0.80 MAPT (0.65) GAALMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL21361478 0.80 DRD2 (0.49) DRD2DRD4SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL27195927 0.79 ALDH1A1 (0.51) GAALMNAALDH1A1L3MBTL1MAPT
SCHEMBL13419225 0.77 KCNH2 (0.44) GAALMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL24233869 0.76 ALDH1A1 (0.38) GAALMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL23102075 0.76 POLB (0.50) DRD2ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G DRD2 2954/4885DRD4 4231/4885GAA 1920/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G DRD2 3081/4885DRD4 4348/4885GAA 2080/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G DRD2 2649/4885DRD4 4056/4885GAA 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.